As our loyal blog readers know, we are great fans of social media, and follow these topics in earnest (here, here, and here). We have just learned that the long-awaited FDA guidance that was promised to come out by year-end will be delayed until the first quarter of 2011 (hat tip: Eye On FDA). While the pharmaceutical industry is clamoring for some clear guidelines (other than those that come from warning letters!), the dream will be deferred for at least a few months (at a minimum).
HPM Web Site
Blogmasters
Get Updates via E-mail
Tweets by @fdalawblog
Disclaimer
- FDA Law Blog is published for informational purposes only; it contains no legal advice whatsoever. Publication of FDA Law Blog does not create an attorney-client relationship. FDA Law Blog is the blog of Hyman, Phelps & McNamara, P.C. (“HPM”) and it is intended primarily for other attorneys and regulatory professionals. No part of FDA Law Blog --whether information, commentary, or other-- may be attributed to HPM's clients. Readers should be aware that HPM represents many companies in the food, drug, medical device, and health care industries, and therefore FDA Law Blog may occasionally report on news that relates to HPM clients. FDA Law Blog will always strive to be unbiased in its reporting. All information on FDA Law Blog should be double-checked for its accuracy and current applicability.
Copyright 2011 Hyman, Phelps & McNamara, P.C.
Blogroll
Awards & Honors
« Are Attorneys the FDA’s New Enforcement Target? | Main | Notorious Affiliate Exclusion Provision of PPACA Repealed »
December 21, 2010
TrackBack
TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a00d8341d150c53ef0148c6f02ed9970c
Listed below are links to weblogs that reference Twitter Delayed is Twitter Denied: DDMAC Social Media Guidance Delayed until 2011:
Verify your Comment
Previewing your Comment
This is only a preview. Your comment has not yet been posted.
Your comment could not be posted. Error type:
Your comment has been saved. Comments are moderated and will not appear until approved by the author. Post another comment
As a final step before posting your comment, enter the letters and numbers you see in the image below. This prevents automated programs from posting comments.
Having trouble reading this image? View an alternate.
Search
Recent Posts
- CDRH Issues Final Appeals Guidance, Q&A About FDASIA Appeals Process
- While We’re Waiting on Bartlett, Some New Preemption Challenges to Consider
- Third Circuit Holds that the FDC Act Preempts Class Action Regarding Absence of Trans Fat and Cholesterol Reducing Effect
- FDA Deploys Section 301(ll) in Battle Against DMAA
- HP&M Director Frank Sasinowski Receives NORD Lifetime Achievement Award
180-Day Exclusivity Tracker
Citizen Petition Tracker
REMS Tracker
Legislation Tracker
Categories
- Advertising and Promotion (DDMAC)
- Advertising and Promotion (Federal Trade Commission)
- Animal Drugs and Feeds
- Controlled Substances
- Cosmetics
- Current Affairs
- Dietary Supplements
- Drug Development
- Drug Enforcement Administration
- Enforcement
- FDA News
- Foods
- Foods and Dietary Supplements
- Fraud and Abuse
- Government Pricing
- Hatch-Waxman
- Health Care
- Health Privacy
- Import/Export
- In Vitro Diagnostic Devices
- Jobs
- Medical Devices
- Miscellaneous
- Orphan Drugs
- OTC Drugs and Cosmetics
- Prescription Drugs and Biologics
- Product Jurisdiction and Combination Products
- Reimbursement
- Tobacco
Comments